Dianthus Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Dianthus Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$2.04M	$6.24M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$177.93M	-$101.86M
Operating income as a percentage of revenue.	-8739.3%	-1633.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$162.34M	-$84.97M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-4.20	$-2.55
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-4.20	$-2.55

Balance Sheet

	2025-12-31	2024-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$51.09M	$22.79M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$530.92M	$374.01M
Everything the company owes — debt, unpaid bills, and other obligations.	$37.52M	$21.53M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$493.40M	$352.48M

Cash Flow Statement

	2025-12-31	2024-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$129.06M	-$78.18M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$213000	$105000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$129.27M	-$78.28M